255 related articles for article (PubMed ID: 34711450)
21. Genetic predisposition to prostate cancer.
Benafif S; Eeles R
Br Med Bull; 2016 Dec; 120(1):75-89. PubMed ID: 27941040
[TBL] [Abstract][Full Text] [Related]
22. Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study.
Karlsson Q; Brook MN; Dadaev T; Wakerell S; Saunders EJ; Muir K; Neal DE; Giles GG; MacInnis RJ; Thibodeau SN; McDonnell SK; Cannon-Albright L; Teixeira MR; Paulo P; Cardoso M; Huff C; Li D; Yao Y; Scheet P; Permuth JB; Stanford JL; Dai JY; Ostrander EA; Cussenot O; Cancel-Tassin G; Hoegel J; Herkommer K; Schleutker J; Tammela TLJ; Rathinakannan V; Sipeky C; Wiklund F; Grönberg H; Aly M; Isaacs WB; Dickinson JL; FitzGerald LM; Chua MLK; Nguyen-Dumont T; ; Schaid DJ; Southey MC; Eeles RA; Kote-Jarai Z
Eur Urol Oncol; 2021 Aug; 4(4):570-579. PubMed ID: 33436325
[TBL] [Abstract][Full Text] [Related]
23. Bringing Prostate Cancer Germline Genetics into Clinical Practice.
Das S; Salami SS; Spratt DE; Kaffenberger SD; Jacobs MF; Morgan TM
J Urol; 2019 Aug; 202(2):223-230. PubMed ID: 30730411
[TBL] [Abstract][Full Text] [Related]
24. Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer.
Darst BF; Dadaev T; Saunders E; Sheng X; Wan P; Pooler L; Xia LY; Chanock S; Berndt SI; Gapstur SM; Stevens V; Albanes D; Weinstein SJ; Gnanapragasam V; Giles GG; Nguyen-Dumont T; Milne RL; Pomerantz M; Schmidt JA; Mucci L; Catalona WJ; Hetrick KN; Doheny KF; MacInnis RJ; Southey MC; Eeles RA; Wiklund F; Kote-Jarai Z; Conti DV; Haiman CA
J Natl Cancer Inst; 2021 May; 113(5):616-625. PubMed ID: 32853339
[TBL] [Abstract][Full Text] [Related]
25. Rare germline genetic variants and risk of aggressive prostate cancer.
Nguyen-Dumont T; MacInnis RJ; Steen JA; Theys D; Tsimiklis H; Hammet F; Mahmoodi M; Pope BJ; Park DJ; Mahmood K; Severi G; Bolton D; Milne RL; Giles GG; Southey MC
Int J Cancer; 2020 Oct; 147(8):2142-2149. PubMed ID: 32338768
[TBL] [Abstract][Full Text] [Related]
26. Germline copy number variation analysis in Finnish families with hereditary prostate cancer.
Laitinen VH; Akinrinade O; Rantapero T; Tammela TL; Wahlfors T; Schleutker J
Prostate; 2016 Feb; 76(3):316-24. PubMed ID: 26552734
[TBL] [Abstract][Full Text] [Related]
27. Germline BLM mutations and metastatic prostate cancer.
Ledet EM; Antonarakis ES; Isaacs WB; Lotan TL; Pritchard C; Sartor AO
Prostate; 2020 Feb; 80(2):235-237. PubMed ID: 31816118
[TBL] [Abstract][Full Text] [Related]
28. [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
Matveev VB; Kirichek AA; Filippova MG; Savinkova AV; Khalmurzaev OA; Lyubchenko LN
Urologiia; 2019 Dec; (5):79-85. PubMed ID: 31808637
[TBL] [Abstract][Full Text] [Related]
29. Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.
Annala M; Struss WJ; Warner EW; Beja K; Vandekerkhove G; Wong A; Khalaf D; Seppälä IL; So A; Lo G; Aggarwal R; Small EJ; Nykter M; Gleave ME; Chi KN; Wyatt AW
Eur Urol; 2017 Jul; 72(1):34-42. PubMed ID: 28259476
[TBL] [Abstract][Full Text] [Related]
30. Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.
Isaacsson Velho P; Silberstein JL; Markowski MC; Luo J; Lotan TL; Isaacs WB; Antonarakis ES
Prostate; 2018 Apr; 78(5):401-407. PubMed ID: 29368341
[TBL] [Abstract][Full Text] [Related]
31. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
[TBL] [Abstract][Full Text] [Related]
32. Detection of Pathogenic Variants With Germline Genetic Testing Using Deep Learning vs Standard Methods in Patients With Prostate Cancer and Melanoma.
AlDubayan SH; Conway JR; Camp SY; Witkowski L; Kofman E; Reardon B; Han S; Moore N; Elmarakeby H; Salari K; Choudhry H; Al-Rubaish AM; Al-Sulaiman AA; Al-Ali AK; Taylor-Weiner A; Van Allen EM
JAMA; 2020 Nov; 324(19):1957-1969. PubMed ID: 33201204
[TBL] [Abstract][Full Text] [Related]
33. KLK3 germline mutation I179T complements DNA repair genes for predicting prostate cancer progression.
Xu J; Shi Z; Wei J; Na R; Resurreccion WK; Wang CH; Sample C; Han M; Zheng SL; Cooney KA; Helfand BT; Isaacs WB
Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):749-754. PubMed ID: 35149774
[TBL] [Abstract][Full Text] [Related]
34. Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.
Carter HB; Helfand B; Mamawala M; Wu Y; Landis P; Yu H; Wiley K; Na R; Shi Z; Petkewicz J; Shah S; Fantus RJ; Novakovic K; Brendler CB; Zheng SL; Isaacs WB; Xu J
Eur Urol; 2019 May; 75(5):743-749. PubMed ID: 30309687
[TBL] [Abstract][Full Text] [Related]
35. Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease.
Mijuskovic M; Saunders EJ; Leongamornlert DA; Wakerell S; Whitmore I; Dadaev T; Cieza-Borrella C; Govindasami K; Brook MN; Haiman CA; Conti DV; Eeles RA; Kote-Jarai Z
Br J Cancer; 2018 Jul; 119(1):96-104. PubMed ID: 29915322
[TBL] [Abstract][Full Text] [Related]
36. Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications.
Brandão A; Paulo P; Teixeira MR
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708810
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines.
Nicolosi P; Ledet E; Yang S; Michalski S; Freschi B; O'Leary E; Esplin ED; Nussbaum RL; Sartor O
JAMA Oncol; 2019 Apr; 5(4):523-528. PubMed ID: 30730552
[TBL] [Abstract][Full Text] [Related]
38. Evaluating Germline Testing Panels in Southern African Males With Advanced Prostate Cancer.
Gheybi K; Jiang J; Mutambirwa SBA; Soh PXY; Kote-Jarai Z; Jaratlerdsiri W; Eeles RA; Bornman MSR; Hayes VM
J Natl Compr Canc Netw; 2023 Mar; 21(3):289-296.e3. PubMed ID: 36898365
[TBL] [Abstract][Full Text] [Related]
39. A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer.
Kote-Jarai Z; Jugurnauth S; Mulholland S; Leongamornlert DA; Guy M; Edwards S; Tymrakiewitcz M; O'Brien L; Hall A; Wilkinson R; Al Olama AA; Morrison J; Muir K; Neal D; Donovan J; Hamdy F; Easton DF; Eeles R; ;
Br J Cancer; 2009 Jan; 100(2):426-30. PubMed ID: 19127258
[TBL] [Abstract][Full Text] [Related]
40. Bayesian predictive model to assess BRCA2 mutational status according to clinical history: Early onset, metastatic phenotype or family history of breast/ovary cancer.
Leon P; Cancel-Tassin G; Bourdon V; Buecher B; Oudard S; Brureau L; Jouffe L; Blanchet P; Stoppa-Lyonnet D; Coulet F; Sobol H; Cussenot O
Prostate; 2021 May; 81(6):318-325. PubMed ID: 33599307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]